Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial)

American Journal of Cardiology

Volumn 103, Issue 10, 2009, Pages 1359-1363

  Dasgupta, Arijit ^a   Steinhubl, Steven R ^b,c   Bhatt, Deepak L ^d   Berger, Peter B ^b   Shao, Mingyuan ^e   Mak, Koon Hou ^f   Fox, Keith A A ^g   Montalescot, Gilles ^h   Weber, Michael A ⁱ   Haffner, Steven M ^j   Dimas, Alexios P ^k   Steg, P Gabriel ^l   Topol, Eric J ^m  

^a UNIVERSITY OF KENTUCKY   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c Medicines Company   (Switzerland)

^d VA BOSTON HEALTHCARE SYSTEM   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f GLENEAGLES HOSPITAL   (Singapore)

^g ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^k HYGEIA HOSPITAL   (Greece)

^l BICHAT HOSPITAL   (France)

^m SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; THROMBOSIS; TREATMENT OUTCOME;

EID: 65449184492     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.01.342     Document Type: Article

References (15)

1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
2. Gawaz M., and Bogner C. Changes in platelet membrane glycoproteins and platelet-leukocyte interaction during hemodialysis. Clin Invest 72 (1994) 424-429
3. Best P.J., Steinhubl S.R., Berger P.B., Dasgupta A., Brennan D.M., Szczech L.A., Califf R.M., and Topol E.J. The efficacy and safety of long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation Trial (CREDO) Trial. Am Heart J 155 (2008) 687-693
4. Keltai M., Tonelli M., Mann J.F., Sitkei E., Lewis B.S., Hawken S., Mehta S.R., Yusuf S., and CURE Trial Investigators. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 14 (2007) 312-318
5. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
6. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993) 673-682
7. Cannon C.P., McCabe C.H., Wilcox R.G., Langer A., Caspi A., Berink P., Lopez-Sendon J., Toman J., Charlesworth A., Anders R.J., et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) Trial. Circulation 102 (2000) 149-156
8. Farid N.A., Payne C.D., Small D.S., Winters K.J., Ernest II C.S., Brandt J.T., Darstein C., Jakubowski J.A., and Salazar D.E. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81 (2007) 735-741
9. Touchette M.A., and Slaughter R.L. The effect of renal failure on hepatic drug clearance. DICP 25 (1991) 1214-1224
10. Talbert R.L. Drug dosing in renal insufficiency. J Clin Pharmacol 34 (1994) 99-110
11. Leblond F., Guevin C., Demers C., Pellerin I., Gascon-Barre M., and Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12 (2001) 326-332
12. Konishi K. Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis. Antimicrob Agents Chemother 30 (1986) 901-905
13. Waehre T., Damås J.K., Pedersen T.M., Gullestad L., Yndestad A., Andreassen A.K., Frøland S.S., Semb A.G., Hansteen V., Gjertsen E., et al. Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost 4 (2006) 2140-2147
14. Steinhubl S.R., Badimon J.J., Bhatt D.L., Herbert J.M., and Luscher T.F. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 12 (2007) 113-122
15. Szalai C., Duba J., Prohászka Z., Kalina A., Szabó T., Nagy B., Horváth L., and Császár A. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis 158 (2001) 233-239